Quanterix Corp (QTRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Quanterix Corp (QTRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Quanterix Announces Leadership Transition Plan Everett Cunningham Steps Down as President and CEO to Accept Another Opportunity Jim Gute, Quanterix’s Chief Commercial Officer, Appointed to the Additional Role of Interim President and CEO Board Has Initiated a Search

Event · Exec change
Person
Everett Cunningham
Title
President and Chief Executive Officer
Action
resigned
Also in this documentExec change · interim

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 18, 2026, 1:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$QTRX
Neutral
medium confidence
Mentioned
$QTRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QTRXNeutralMed
01

Why it matters

The company reaffirmed its 2026 business outlook while appointing an interim CEO and initiating a search for a permanent replacement, signaling continuity but acknowledging a leadership reset.

02

Market read

This is a primary disclosure of an immediate CEO departure and interim appointment, which can drive near-term sentiment and positioning ahead of any further leadership or strategy updates.

03

What to watch

Investors may focus on whether the company’s reaffirmed 2026 outlook implies confidence in near-term execution despite the CEO change, and on any forthcoming details from the executive search process.

Relevance 6/10Novelty 6/10Timing: effective immediately, filed pre-market today

Background

Quanterix filed an 8-K for Item 5.02 and Regulation FD, detailing a leadership transition plan and compensatory arrangements tied to the CEO change.

Company-level read

Ticker impact

$QTRXNeutralMedium confidence
Context

Quanterix announced Everett Cunningham stepped down as President and CEO, appointing Jim Gute as Interim CEO while it searches for a new CEO.

Expected impact

Likely choppy trading as investors price in transition risk and wait for details on the CEO search and any compensation or strategy changes.

Evidence & confidence

The filing is a primary disclosure of an immediate CEO change and interim appointment, but it does not provide new financial guidance numbers beyond reaffirming the 2026 outlook.

Market effects

May increase attention on management stability across precision diagnostics and biomarker platforms, but no direct sector-wide policy or product catalyst is disclosed.

Limited regional spillover; this is company-specific leadership and governance news.

Global relevance is modest, as the event is an internal executive transition with no stated international regulatory or commercial contract impact.

Counterpoint

Interim CEO appointment from within the commercial leadership team could reduce disruption and support continuity in revenue execution while the board runs the search.

Key entities

  • Quanterix Corp

    Precision biomarker science company filing the 8-K for CEO departure and interim CEO appointment.

  • Everett Cunningham

    Stepped down as President and CEO and as a member of the board, effective immediately.

  • Jim Gute

    Chief Commercial Officer appointed Interim President and CEO while the board searches for a new CEO.

  • Board of Directors

    Initiated a search for a new CEO and engaged an executive search firm.

Related articles

$QTRXMed

What Quanterix (QTRX) Said on Its Q3 Earnings Call

Quanterix (QTRX) reported a Q3 net loss of $21.6M, improved from last year. Adjusted EBITDA loss was $12.2M. Gross margin rose to 47.4%. LucentAD test volume doubled, but revenue from diagnostics fell to $1.2M. The company expects 2026 gross margin of 48-50% and $70M cash. Alzheimer's test discussions with FDA continue, with no clearance date given.

$QTRXMed

Quanterix Releases Financial Results for the Third Quarter of 2026

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Third Quarter of 2026 Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities Initiatives to accelerate commercial effectiveness position the Company for growth in rest o

$QTRXHighAI 9/10

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

$QTRXMed

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.